Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Lucentis Stories

2006-08-29 05:04:54

By Sam Cage ZURICH (Reuters) - Drugmaker Novartis AG said on Tuesday that Switzerland had become the first European country to approve the company's Lucentis drug as a treatment for a leading cause of blindness in people over age 50. The U.S. Food and Drug Administration has already approved Lucentis, a drug developed by U.S. firm Genentech Inc., to treat vision loss from the so-called "wet," or more severe form of age-related macular degeneration (AMD). Genentech has the commercial...

2006-06-30 19:20:42

By Lisa Richwine WASHINGTON (Reuters) - A Genentech Inc. drug that reversed vision loss in some patients won U.S. approval on Friday for treating the leading cause of blindness in the elderly. Injected into the eye monthly, the drug Lucentis maintained vision in 95 percent of patients with the wet form of age-related macular degeneration (AMD) who were treated for 12 months. Eyesight improved in one-third of patients, the Food and Drug Administration said. "The 95 percent retention...

2005-07-18 11:59:19

NEW YORK (Reuters) - Genentech Inc. on Monday said the average patient with age-related macular degeneration who received its experimental drug Lucentis could read an additional seven letters of a reading chart, compared with a vision loss of 10.5 letters among those who received sham injections. The favorable difference, amounting to about 17 letters, was seen in a one year-trial, whose results were presented by researchers at a medical meeting in Montreal. Genentech has said that U.S....